ACHV NASDAQ
Achieve Life Sciences, Inc.
1W: -20.6%
1M: +8.8%
3M: +7.7%
YTD: -7.4%
1Y: +41.1%
3Y: -41.8%
5Y: -51.1%
$4.69
+0.09 (+1.96%)
Weekly Expected Move ±13.6%
$4
$5
$5
$6
$7
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$250.5M
52W Range2-6.15
Volume805,184
Avg Volume1,185,358
Beta2.25
Dividend—
Analyst Ratings
Company Info
CEORichard A. Stewart
Employees25
SectorHealthcare
IndustryBiotechnology
IPO Date1995-10-12
Websiteachievelifesciences.com
1040 West Georgia Street
Vancouver, BC V6E 4H1
CA
Vancouver, BC V6E 4H1
CA
14256861500
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Martin Christopher N | A-Award | 47,250 | $5.59 | 2026-05-11 |
| Martin Christopher N | 0 | — | 2026-05-11 | |
| Goldberg Andrew D. | A-Award | 11,706,270 | — | 2026-04-18 |
| Goldberg Andrew D. | A-Award | 3,601,929 | $4.25 | 2026-04-18 |
| Goldberg Andrew D. | A-Award | 1,800,965 | — | 2026-04-18 |